Black Diamond Therapeutics, Inc. (BDTX) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-03-20

Key Insights

The reporting person, Ali Behbahani, acquired 6,919 shares of Black Diamond Therapeutics, Inc. (BDTX) common stock on March 20, 2026 at $2.15 per share, increasing his direct ownership to 93,568 shares.
Behbahani also holds an indirect beneficial ownership of 4,448,757 shares through his role as a manager of NEA 16 GP, LLC, the general partner of NEA Partners 16, L.P., the direct beneficial owner of the securities.
The acquisition of shares by the director suggests confidence in the company's prospects and aligns Behbahani's interests with those of other shareholders.

Want the newest filings?

This analysis covers the filing from 2026-03-20. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-20

The reporting person, Prakash Raman, acquired 6,105 shares of the company's common stock at $2.15 per share, increasing their direct ownership to 37,132 shares.
The share acquisition was made in lieu of cash compensation for the reporting person's service as a non-employee director, indicating their continued commitment to the company.
The transaction price of $2.15 per share reflects the closing market price of the company's stock on the previous trading day, suggesting the acquisition was made at fair market value.

Filed: 2026-01-23

Brent Hatzis-Schoch, the Chief Operating Officer and General Counsel of Black Diamond Therapeutics, Inc. (BDTX), was granted a stock option to acquire 250,000 shares of the company's common stock.
The stock option has a grant date of January 21, 2026 and an exercise price of $2.57 per share, with 25% of the shares vesting on January 21, 2027 and the remaining shares vesting in 36 equal monthly installments thereafter.
This option grant suggests that the company is incentivizing and retaining its key executive, which could be positive for the company's long-term growth and stability.

Filed: 2026-01-23

The reporting person, Mark A. Velleca, President and CEO of Black Diamond Therapeutics, Inc., has been granted a stock option to acquire 600,000 shares of the company's common stock at an exercise price of $2.57 per share.
The option vests over a 4-year period, with 25% of the shares vesting on January 21, 2027, and the remaining shares vesting in 36 equal monthly installments thereafter.
This transaction indicates the company's commitment to retaining its leadership and aligning the CEO's interests with those of shareholders through equity-based compensation.

Filed: 2026-01-23

Sergey Yurasov, the Chief Medical Officer of Black Diamond Therapeutics, has been granted a stock option to acquire 250,000 shares of the company's common stock at an exercise price of $2.57 per share.
The option vests over a four-year period, with 25% of the shares vesting on January 21, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to Yurasov's continued service.
This stock option grant represents a vote of confidence in Yurasov's leadership and his ability to contribute to the company's growth and success in the coming years.

Filed: 2026-01-23

Elizabeth Buck, the Chief Scientific Officer of Black Diamond Therapeutics, Inc., has been granted a stock option to acquire 250,000 shares of the company's common stock.
The option vests over a multi-year period, with 25% vesting on January 21, 2027 and the remaining 75% vesting in equal monthly installments thereafter, subject to her continued service.
This stock option grant suggests that the company is incentivizing its senior leadership to drive the company's long-term success and align their interests with those of shareholders.

Filed: 2026-01-23

Erika Jones, the Senior Vice President, Finance and Corporate Controller of Black Diamond Therapeutics, Inc. (BDTX), has been granted a stock option for 200,000 shares of the company's common stock, with 25% vesting on January 21, 2027 and the remainder vesting in 36 equal monthly installments thereafter.
The stock option has an exercise price of $2.57 per share and will expire on January 20, 2036, indicating a long-term incentive for the reporting person to contribute to the company's success.
This insider transaction represents a significant equity award, potentially signaling management's confidence in the company's future prospects and aligning the reporting person's interests with those of shareholders.

Other reports for Black Diamond Therapeutics, Inc.

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.